Evidence map›Paper›PMID 39628313›Full record

ArticlePharmacogenomics2024

Do CYP2D6 genotypes affect oxycodone dose, pharmacokinetics, pain, and adverse effects in cancer?

Aaron K Wong, Sara Vogrin, Pal Klepstad, Justin Rubio, Brian Le, Jennifer Philip, Andrew A Somogyi

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmacogenomics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Aaron K WongDepartment of Palliative Care, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0002-6507-1219
Sara VogrinDepartment of Medicine, St Vincent's Hospital Melbourne, University of Melbourne, Victoria, Australia.
Pal KlepstadDepartment Intensive Care Medicine, St. Olavs University Hospital, Trondheim, Norway.
Justin RubioPrincipal Research Fellow, Florey Institute of Neuroscience & Mental Health, Victoria, Australia.
Brian LeDepartment of Palliative Care, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Jennifer PhilipDepartment of Palliative Care, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Andrew A SomogyiClinical and Experimental Pharmacology, Discipline of Pharmacology, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo examine the associations between PATIENTS &

methodsThis multi-center prospective cohort study included clinical data, questionnaires (pain and adverse effects), and blood (pharmacokinetics, DNA). Negative binomial regression and logistic regression were used.

resultsWithin 33 participants, there were no differences in oxycodone response between CYP2D6 intermediate/poor metabolisers compared to normal metabolisers.Higher plasma noroxycodone and noroxycodone/oxycodone concentration ratios had higher odds of uncontrolled average pain (OR 2.44 (95%CI 1.00-5.95),

conclusionsThere was no observed benefit in

Indexed as

Analgesics, OpioidCytochrome P-450 CYP2D6GenotypeNeoplasmsOxycodoneAdultAgedCancer PainCytochrome P-450 CYP3ADose-Response Relationship, DrugFemaleHumansMaleMiddle AgedMorphinansProspective StudiesAnalgesics, OpioidCytochrome P-450 CYP2D6Cytochrome P-450 CYP3AMorphinansnoroxycodoneOxycodoneadvanced canceranalgesicsOpioidpalliative carepharmacogenetics

Identifiers

PMID39628313
PMCPMC11703413

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.